The lack of urgency at the FDA, as it is in the defense space, is alarming.
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
Investors are using the available weakness to buy the stock.
Plus, Zscaler largely delivers for its owners with its latest results.
And It comes after one of the best days of the year for the biotech sector.
The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
This COVID-19 vaccine is the potential savior of more than just the market.
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.